RECRUITINGINTERVENTIONAL
Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
Implementing Non-invasive Circulating Tumor DNA and Circular DNA Analysis in Patients With Localized Pancreatic Cancer to Optimize the Pre- and Postoperative Treatment: Predicting Recurrence and Survival and Changing Prognosis Over Time
About This Trial
The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if plasma ctDNA combined with CT scan and endoscopic ultrasound surveillance increases the median overall survival compared with standard-of-care surveillance.
Who May Be Eligible (Plain English)
Who May Qualify:
- Sub-study 1: Suspicion of PDAC tumor stage I-III, scheduled for pancreatic resection, with or without preoperative neoadjuvant chemotherapy.
- Sub-study 2: .
- PDAC tumor stage I-III
- Has received intended curative resection (R0/R1) of PDAC
- No signs of local recurrence or metastatic disease at a CT scan 4 months after the operation
Who Should NOT Join This Trial:
- Other cancers (excluding skin cancer other than melanoma) later than 3 years before inclusion
- Patients who are unlikely to comply with the protocol, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Sub-study 1: Suspicion of PDAC tumor stage I-III, scheduled for pancreatic resection, with or without preoperative neoadjuvant chemotherapy.
* Sub-study 2: .
* PDAC tumor stage I-III
* Has received intended curative resection (R0/R1) of PDAC
* No signs of local recurrence or metastatic disease at a CT scan 4 months after the operation
Exclusion Criteria:
* Other cancers (excluding skin cancer other than melanoma) later than 3 years before inclusion
* Patients who are unlikely to comply with the protocol, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study
Treatments Being Tested
DIAGNOSTIC_TEST
ctDNA
ctDNA guided surveillance
Locations (5)
Aalborg Universitetshospital
Aalborg, Denmark
Aarhus Universitetshospital
Aarhus, Denmark
Copenhagen University Hospital - Rigshospitalet
Copenhagen, Denmark
Copenhagen University Hospital - Herlev and Gentofte
Herlev, Denmark
Odense Universitetshospital
Odense, Denmark